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fered from high levels of anxiety, stress, and depression. The most frequent co-
morbidities included hypertension, coronary artery diseases, hyperlipidemia,
diabetes, obesity, depression, other skin diseases, and inflammatory bowel dis-
ease. Psoriasismay also confer an independent risk of acutemyocardial infarction.
CONCLUSIONS: Psoriasis was reported to have adverse effects on patients’ quality
of life including daily activities, social life, and productivity. Clinical burdens asso-
ciated with psoriasis included a number of serious co-morbidities. The evidence
retrieved as part of this systematic literature review well addressed the clinical
importance of psoriasis in Asia Pacific countries.
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OBJECTIVES: This study examined the opioid-sparing effectiveness, analgesic ef-
ficacy and tolerability of postoperative administration of parecoxib in total knee
arthroplasty (TKA) patients. METHODS: We performed a retrospective study of
enrollees received patient-controlled analgesia (PCA, consisted of morphine 1
mg/ml and fentanyl 30 mcg/ml) with or without single-dose of intravenous 40 mg
parecoxib following TKA from November 2010 through April 2011. Effect was as-
sessed by the amount of PCA used, pain intensity, length of hospital stay (LOS),
satisfaction score and adverse events. RESULTS: Nine patients under PCA with
parecoxib as the parecoxib group and 73 patients without parecoxib as the con-
trolled group were evaluated. PCA consumption was observed to be reduced in the
parecoxib group by 17.2 %, 25.5 % and 39.8 % less than the controlled group at 24 h,
48 h, and 72 h after surgery. Pain at movement improved significantly at 48 h and
72 h for the parecoxib group with visual analogue score (VAS). There were no
significant differences in pain scores at rest and LOS, however, between those who
received parecoxib or not. Satisfaction was described as “good, fair, and poor” by 0
%, 89%, and 11% in the parecoxib group, respectively, comparedwith 4%, 81%, and
15 % of the controlled group. The overall incidences of adverse events were re-
ported for 78 % of patients with parecoxib and 71 % of patients without parecoxib.
CONCLUSIONS: In this study, postoperative administration of parecoxib demon-
strated benefit in terms of PCA consumption and VAS score at movement. There-
fore, it seemed that parecoxib provided opioid-sparing and analgesic effect. Also,
the parental preparation of parecoxibmay be especially useful when patients were
unable to take oral medication or were experiencing nausea and vomiting.
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OBJECTIVES:Obesity and overweight constitute a significant public health issue in
New Zealand. The aim of this systematic review was to formally assess the evi-
dence on the effectiveness of selected obesity interventions. METHODS: The first
phase of this research involved a wide-ranging scoping search of the literature to
identify population-based obesity-prevention interventions. The search was con-
ducted using the Embase andMedline databases, a general internet search and via
the contributions of the stakeholder reference group. A total of 95 relevant primary
prevention interventionswere found, with 38 of these assessed in Australia or New
Zealand. The research team and the stakeholder reference group considered the
results of the scoping search and selected 16 interventions that appeared to be
effective using a weight-based outcome for full systematic review. RESULTS: The
selected interventions were based on both nutrition and physical activity in a
variety of age groups and settings (pre-school, school, tertiary education, commu-
nity, primary care and workplace). Interventions generally showed greater reduc-
tions in body mass index (BMI), BMI z-score, weight, weight to height ratio, waist
circumference and the incidence of being overweight or obese compared with
controls. In a school-basednutrition andphysical activity intervention inAustralia,
children in the intervention group gained significantly less weight compared with
the control group (-0.92 kg; P0.03). In a study of general health screening con-
ducted in Denmark, the body mass index of adults receiving the intervention in-
creased 0.6 kg/m2 less that those not receiving the intervention. CONCLUSIONS: A
number of interventions were shown to have the potential to prevent obesity in a
range of populations and settings. Themost cost-effective interventions for obesity
prevention were a school-based programme for children and general health
screening and advice for adults in a primary care setting.
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OBJECTIVES: Lead toxicity has been labeled as a major health problem globally
with limited therapeutic options. Literature reveals controversial reports on the
lead detoxifying potential of ascorbic acid (vitamin C). The aim of this study was to
see if vitamin C supplementation reduces lead levels of blood in adult subjects
exposed to lead.METHODS:After ethical approval and informed consent the traffic
police study subjects (all male) were randomly divided into two groups each con-
taining 40 subjects. One group received 500 mg vitamin C, while the second group
was given 1000 mg orally daily for a period of one month. Blood samples were
collected at 0, 15, and 30 days of treatment and lead levels were analyzed from the
PCSIR Lab, Karachi using atomic absorption spectrophotometer. RESULTS: The
data showed raised levels of lead in study subjects of both groups (21.74 1.62 and
22.51  1.28 mcg/dl; mean  SEM; N40) compared to the safe limit ( 10 mcg/dl)
recommended by WHO. The treatment with vitamin C (500 mg) reduced the lead
levels to 16.91 1.08mcg/dl (N29) after 15 days treatment (P0.01), while the lead
level after 30 days treatment was further reduced to12.61  1.50 mcg/dl (N  36;
p0.001 compared to control, 21.74  1.62). In the second group subjects, which
received 1000 mg vitamin C, the lead level after 15 days treatment was 15.800.89
mcg/dl (N 33; P0.001)), with no further drop (P0.05) after 30 days treatment, as
the resultant lead levelwas 14.64 1.05mcg/dl (N31).CONCLUSIONS:These data
indicate that vitamin C has a dose and time-dependent lead-detoxifying effect and
that vitamin C supplementation may be an effective, safe and economical method
in reducing blood lead levels in chronically exposed subjects such as traffic police.
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OBJECTIVES:A validated screening tool for the diagnosis of fibromyalgia (ACR 2010
FM-STD) had been introduced in Thailand. The aim of this study is to explore with
the FM-STD the prevalence of fibromyalgia (FM) and estimate its burden of disease
(BOD) within the community of Bangkok, Thailand. METHODS: A cross-sectional
nonclinical survey process was conducted in urban and suburban Bangkok during
August-December 2011. The questionnaire was designed to collect data related to
pain, likelihood of FM diagnose, pain impact and treatment patterns. Primary in-
terviewswere conducted by field researchers. Every respondent, whose scoresmet
the diagnostic criteria of FM,were subsequently referred to further investigation by
our research physicians who confirmed final diagnoses of those cases. RESULTS:
One thousand respondents fromvarious socio-economic backgrounds participated
in the survey. Six of them (0.6%) were medically found positive to FM; their mean
age (range): was 47.67 (33-63) years. Mean widespread pain index (WPI) and symp-
tom severity (SS) scale score (range): 10.17 (7-16) and 7.83 (7-12), respectively. Lower
back and right shoulder girdle were the first and second most frequent pain loca-
tions. Intermittent throbbing pain was the most general presentation among FM
cases. For key FM features, all six respondents reported, mild to severe intensity
fatigue and waking unrefreshed while altogether cognitive impairment was re-
ported unproblematic. Furthermore, FM had strong impact to daily activities, par-
ticularly for sleep, walk and routine work. Mean ability to accomplish work de-
clined up to 71.67% (60%-90%). All cases required aminimum onemonthly therapy
to manage their pain symptoms; massage/spa being the most frequent treatment
method selected in this study. Average monthly out-of-pocket expense, related to
pain management was US$16.11 (0-33.33). CONCLUSIONS: This is the first epide-
miological survey of FM in Thailand. Therefore, study’s findings will generate a
better understanding of FM problem among Thai health care providers.
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OBJECTIVES: To describe the prevalence and treatment status of hemophilia A
(HA), hemophilia B (HB), hemophilia C (HC) and Von Willebrand disease (VWD) in
mainland China based on existing data, and to estimate the cost of switching from
on-demand therapy to prophylaxis.METHODS:We conducted a systematic litera-
ture review in Aug, 2011 using PubMed, EMBASE, and Cochrane Library in English
and CBM, CNKI, VIP, Wanfang Database in Chinese. No retrieval limitation was set.
In addition, we carried out a search of general and targeted hemophilia related
websites. Reference lists of key reviews were hand-searched for further relevant
researches. Studies providing data of prevalence or cost of hemophilia inmainland
China were included. Meta-analysis was done using the generic inverse variance
model. RESULTS: 22 epidemiological and 16 economic studies were included for
the analysis. The weighted prevalence of hemophilia (HAHBHCVWD) was 3.6
per 100,000 (95%CI: 2.7-4.9 per 100 000).We estimated the number of hemophiliac in
mainland china to be 49,339 based on the data from the 6th nationwide census. The
official registration number of hemophiliac now is 9804. More than 50% of hemo-
philiacs inmainlandChinawere un-treated or treated occasionally. In the choice of
treating product, less than 50% used pure blood coagulation factors. Less than 10%
received prophylaxis. Based on the cost-effective study, low dose prophylaxis was
a cost-saving strategy compared to on-demand therapy. The frequency of bleeding
could be reduced by 80% and the life of hemophiliac would be close to normal if
extra CNY2.66 billion (CNY53845per case) were invested every year.
CONCLUSIONS: The prevalence of hemophilia in mainland China is underesti-
mated. Registration management has to be improved. Patients with hemophilia
lack treatment generally. It is practical to consider switching the treatment of
hemophilia from on-demand therapy to low dose prophylaxis.
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OBJECTIVES: Chronic hepatitis B (CHB) is a major health problem in Taiwan where
an estimated two million people are infected with the virus, with many being
untreated. The disease is associated with a high risk of long term hepatic compli-
cations including cirrhosis and hepatocellular carcinoma (HCC). Treatment with
anti-virals such as entecavir reduces the risk of complications andmay lead to long
term cost savings. The aim of this economicmodelling studywas to investigate the
socioeconomic burden of untreated CHB in Taiwan and assess the economic ben-
efits of treatment. METHODS: A Markov model was developed that comprised
health states describing themanagement and consequences of CHB. Data from the
Taiwanese observational REVEAL cohort were used to estimate the risk of CHB
complications. Direct costs of complicationswere derived from literature and prev-
alence estimates were included to calculate the burden of disease amongst 30-59
year olds eligible for treatment in Taiwan. The model compared the economic
impact of doubling the number of eligible patients treated with entecavir on the
incidence of hepatic complications and associated costs. Themodelwas conducted
from a Taiwanese payer perspective with a 40 year time horizon. RESULTS: Treat-
ment of more eligible patients reduced the number of CHB complications over 40
years and was associated with a 1.06% (NTD 9.1 billion) reduction in total costs for
all diagnosed patients. Inclusion of productivity losses accentuated this with rela-
tive cost savings of 1.68% (NTD 17.2 billion). Based upon this setting, cost savings
would be realised by year 15. CONCLUSIONS: CHB is likely to have a substantial
economic impact over the next 40 years in Taiwan. Treating a greater proportion of
patients could alleviate this burden and lead to cost savings. Furthermore, treating
more patients is predicted to reduce productivity losses, improve quality of life,
and reduce mortality.
PSY8
BUDGET IMPACT ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF
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OBJECTIVES: To estimate the budgetary consequence of adding Ustekinumab to
the reimbursement drug list in Thailand. METHODS: From payer’s perspective, a
5-year budget impact model was developed based on the current treatment algo-
rithm and reimbursement criteria for moderate to severe chronic plaque psoriasis.
We assumed the current biologic reimbursement program for psoriasis in civil
servant medical benefit scheme (CSMBS) was expanded to cover all Thai popula-
tion. Annual budget impact assessment was a result of changes of current mix of
biologic therapies by introduction of Ustekinumab. This use is as 1st or 2nd biologic
agent in patients with inadequate response from systemic therapies or other bio-
logics, respectively. Current and future market mix data of biologic therapies was
estimated by experts’ opinions, and products’ efficacy and epidemiology data was
derived from literature. Cost variables included medical care costs: biologic acqui-
sition costs, physician visits, monitoring lab tests and inadequate response care.
Univariate sensitivity analysis was conducted to assess the model robustness.
RESULTS: Ustekinumab’s inclusion showed the average total budget spending of
260 million baht per year (226 – 309 million baht from 1st - 5th year respectively).
Comparing to current scenarios with two biologics available, we found the dimi-
nution of total budget around 81 million baht in 5-yr period, accounting for 0.14
million baht per patient. Average budget growth rate was slightly lower with the
inclusion of Ustekinumab (9.90% vs. 11.75%). Comparative total cost per responder
was found lowest in Ustekinumab followed by Infliximab and Etanercept respec-
tively. These results weremainly driven by the number of patients on biologics and
distribution of patients among the available therapies. CONCLUSIONS: The addi-
tion of Ustekinumab to the current biologic reimbursement list provides more
efficient management approach for the treatment budget of moderate to severe
chronic plaque psoriasis in Thailand.
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OBJECTIVES: Systemic lupus erythematosus(SLE) is a chronic autoimmune disor-
der that may affect basically every organ of the body, such as the skin, joints,
kidneys, lungs and nervous system. The aim of this study was to demonstrate the
cost of organ damage cause by SLE. METHODS: A population-based dataset from
the Taiwan’s National Health Insurance Research Dataset (NHIRD) from 2006 to
2010 was used to collect SLE caused organ damage related medical cost. The cases
of SLE were identified according to the ICD-9-CM code 710.0 and catastrophic ill-
ness certificates. SLE related organ damage condition is defined based on the Sys-
temic Lupus International Collaborative Clinics/American Rheumatology (SLICC/
ACR) Damage Index, which contains 41 damage items in 12 systems that are
specific comorbidities associated with SLE or damage due to toxicity of SLE treat-
ment. ICD-9-CM codes were also used for organ damage conditions. To avoid dou-
ble-counting, SLE cases were only included if single comorbidity is observed.
RESULTS:A total number of 22,258 SLE patients were identified and used to extract
cost data of organ damage. Number of prevalent cases increased from 14,748 in
2006 to 18,047 in 2010, and prevalence rates permillion populations increased from
644.7 (623.0 after adjustment) in 2006 to 779.2 (729.9 after adjustment) in 2010.
Among 41 damage items, two of them (shrinking lung andminor tissue loss) do not
have corresponding ICD-9-CM codes. Recurrent cerebral vascular accident or re-
section, cardiomyopathy, and recurrent myocardial infarction caused most medi-
cal expenditures, and mean costs incurred in the first year were NT$ 502,171, NT$
498,871, and NT$ 357,979, respectively. CONCLUSIONS: Organ damages caused by
SLE have incurred tremendous resource utilization to health care system in Tai-
wan. New treatment which can avoid organ damages with neuropsychiatric, renal
and cardiovascular systems is needed for SLE patients.
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OBJECTIVES: Parenteral nutrition is a form of nutritional support administered via
an intravenous catheter. Kabiven is a simple TPN solution that consists of a three
chamber bag and the individual chambers contain glucose- and amino acid solu-
tions, and fat emulsion, respectively. Kabiven may effect serum albumin levels for
malnutrition patient and cost savings to patients receiving tradition TPN.
METHODS: This was a retrospective study in a regional hospital from January 1,
2011 to December 31, 2011. We collected data on patients admitted to ward care
programs who are consulted TPN group for nutrition suggest, a total 164 who are
consulted TPN group than received kabiven for nutrition support during their hos-
pitalization.Monitor serumalbuminwas performed before and after kabiven given
were rospective criteria. RESULTS: The 164 patient included 108 male ( 65.9%) and
56 female (34.1%) GAverage length of stay was 14.3 days (10-30 days; 51.2%) GAver-
age age at 77.2y/o (70-79y/o,33%). The result elevated serum albumin levels 39%(
1.2 g/dl, 25% G0.8 g/dl, 17%G0.7 g/dl, 15%), same serum albumin level 44%,
decrease serum albumin levels 17%. CONCLUSIONS: This study demonstrated that
the simple TPN solutions (kabiven) may significant elevated serum albumin levels
for malnutrition patient and significant cost savings to patients receiving tradition
TPN.
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OBJECTIVES: To describe the prevalence and the treatment status of hemophilia A
(HA), hemophilia B (HB) andVonWillebrand disease (VWD) in India, Russia, Taiwan
and Turkey based on existing data, and to compare prophylaxis with on-demand
therapy. METHODS: We conducted a systematic literature review in Aug, 2011
using PubMed, EMBASE, and Cochrane Library. No retrieval limitation was set. We
also carried out general and targeted internet searches of hemophilia related web-
sites. Reference lists of key reviews were hand-searched for further researches.
Studies providing data of prevalence, treatment or cost of hemophilia in India,
Russia, Taiwan and Turkey were included. Noteexpress 2 was used to manage the
literatures. Meta-analysis was done using the generic inverse variance model.
RESULTS:Overall, 7 epidemiological and 15 economic studieswere included for the
analysis. The prevalence of hemophilia in India, Russia, Taiwan and Turkey was
2.27 per 100 000 (HAHB), 5.12 per 100 000 (HAHBVWD), 3.61 per 100 000 (HA)
and 4.93 per 100 000 (HAHBVWD) respectively. In India, about 15% patients
received no treatment, 47.5% patients used previous blood transfusion, 12.5% used
cryoprecipitate and 25% used factor concentrate. 37% of patients used prophylaxis
in Russia. In Turkey, prophylaxis was superior to on-demand therapy even when
given in a twice-weekly period with intermediate concentrates. Annual extra ex-
penditure of below $5000 per case with prophylaxis compared to on-demand ther-
apywould be needed to permit hemophiliac children to achieve similar capacity as
unaffected ones. In Taiwan, approximately $2 million per year would be added to
the cost of treatment by having all severe HA patients receive secondary prophy-
laxis instead of on-demand therapy while 12566 bleeding would be prevented.
CONCLUSIONS: The prevalence of hemophilia is different among those 4 districts.
Hemophiliacs lack adequate treatment generally. It is practical to switch from
on-demand therapy to Prophylaxis.
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OBJECTIVES: To explore peri-operative bleeding and its relationship with patient
morbidity, mortality and increased health care costs in Hong Kong. METHODS:
EMBASE andMedline databaseswere searched to identify relevant epidemiological
and economic studies. To ensure pertinence of the data, only studies published in
the last 15 years were considered. Relevant studies were identified using a priori
defined inclusion criteria relating to the patient population, setting and outcomes
of interest. RESULTS: Eighteen studies were included in this systematic review.
Themean volume of blood loss ranged from 20–2200mL. Laparoscopic procedures
were generally associated with lower blood loss (20–350 mL), while orthognathic
and liver surgery were associated with greater blood loss (600–2200 mL). Similarly,
the mean volume of blood transfused varied by surgical procedure ranging from
0.17 units (head and neck surgery) to 1.8 units (orthognathic surgery).With the cost
of 1 unit of whole blood estimated at US$200 in Hong Kong, the need for transfu-
sions potentially represent a substantial cost to patients and the health care sys-
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